327 related articles for article (PubMed ID: 25844677)
1. HER2 testing in gastric and gastroesophageal adenocarcinomas.
Vakiani E
Adv Anat Pathol; 2015 May; 22(3):194-201. PubMed ID: 25844677
[TBL] [Abstract][Full Text] [Related]
2. HER2 testing in gastric cancer.
Albarello L; Pecciarini L; Doglioni C
Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
[TBL] [Abstract][Full Text] [Related]
3. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.
Wang T; Hsieh ET; Henry P; Hanna W; Streutker CJ; Grin A
Hum Pathol; 2014 May; 45(5):970-5. PubMed ID: 24656529
[TBL] [Abstract][Full Text] [Related]
4. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.
Kunz PL; Mojtahed A; Fisher GA; Ford JM; Chang DT; Balise RR; Bangs CD; Cherry AM; Pai RK
Appl Immunohistochem Mol Morphol; 2012 Jan; 20(1):13-24. PubMed ID: 21617522
[TBL] [Abstract][Full Text] [Related]
5. HER2 Genetic Heterogeneity in Gastric Cancer: Evaluation According to the College of American Pathologists Breast Cancer Criteria.
Treacy AD; Karamchandani JR; Streutker CJ; Grin A
Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):628-32. PubMed ID: 25611242
[TBL] [Abstract][Full Text] [Related]
6. HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options.
Koltz BR; Hicks DG; Whitney-Miller CL
Biotech Histochem; 2012 Jan; 87(1):40-5. PubMed ID: 21745161
[TBL] [Abstract][Full Text] [Related]
7. Pathologic diagnostics of HER2 positivity in gastroesophageal adenocarcinoma.
Koopman T; Louwen M; Hage M; Smits MM; Imholz AL
Am J Clin Pathol; 2015 Feb; 143(2):257-64. PubMed ID: 25596252
[TBL] [Abstract][Full Text] [Related]
8. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
Bang YJ
J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
[TBL] [Abstract][Full Text] [Related]
10. HER2 testing in gastric cancer: a practical approach.
Rüschoff J; Hanna W; Bilous M; Hofmann M; Osamura RY; Penault-Llorca F; van de Vijver M; Viale G
Mod Pathol; 2012 May; 25(5):637-50. PubMed ID: 22222640
[TBL] [Abstract][Full Text] [Related]
11. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
[TBL] [Abstract][Full Text] [Related]
12. A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.
Gomez-Martín C; Lopez-Rios F; Aparicio J; Barriuso J; García-Carbonero R; Pazo R; Rivera F; Salgado M; Salud A; Vázquez-Sequeiros E; Lordick F
Cancer Lett; 2014 Aug; 351(1):30-40. PubMed ID: 24943493
[TBL] [Abstract][Full Text] [Related]
13. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?
Lorenzen S; Lordick F
Curr Opin Oncol; 2011 Jul; 23(4):396-402. PubMed ID: 21505336
[TBL] [Abstract][Full Text] [Related]
14. Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia.
Fox SB; Kumarasinghe MP; Armes JE; Bilous M; Cummings MC; Farshid G; Fitzpatrick N; Francis GD; McCloud PI; Raymond W; Morey A
Am J Surg Pathol; 2012 Apr; 36(4):577-82. PubMed ID: 22314190
[TBL] [Abstract][Full Text] [Related]
15. A survival guide to HER2 testing in gastric/gastroesophageal junction carcinoma.
Subasinghe D; Acott N; Kumarasinghe MP
Gastrointest Endosc; 2019 Jul; 90(1):44-54. PubMed ID: 30928424
[TBL] [Abstract][Full Text] [Related]
16. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
Hechtman JF; Polydorides AD
Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
[TBL] [Abstract][Full Text] [Related]
17. HER2 Heterogeneity in Gastroesophageal Cancer Detected by Testing Biopsy and Resection Specimens.
Fazlollahi L; Remotti HE; Iuga A; Yang HM; Lagana SM; Sepulveda AR
Arch Pathol Lab Med; 2018 Apr; 142(4):516-522. PubMed ID: 28782986
[TBL] [Abstract][Full Text] [Related]
18. Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India.
Nadaf AS; Rani H; Dinesh US
Asian Pac J Cancer Prev; 2018 May; 19(5):1381-1385. PubMed ID: 29802704
[TBL] [Abstract][Full Text] [Related]
19. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
Van Cutsem E; Bang YJ; Feng-Yi F; Xu JM; Lee KW; Jiao SC; Chong JL; López-Sanchez RI; Price T; Gladkov O; Stoss O; Hill J; Ng V; Lehle M; Thomas M; Kiermaier A; Rüschoff J
Gastric Cancer; 2015 Jul; 18(3):476-84. PubMed ID: 25038874
[TBL] [Abstract][Full Text] [Related]
20. HER2 in situ hybridization in gastric and gastroesophageal adenocarcinoma: comparison of automated dual ISH to FISH.
Grin A; Brezden-Masley C; Bauer S; Streutker CJ
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):561-6. PubMed ID: 23455182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
